Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

Not Applicable

Completed

• Conditions: Healthy Adults
• Interventions: Dietary Supplement: Coromega Nectar; Dietary Supplement: Barleans Swirl; Dietary Supplement: Nordic Omega-3 Softgel; Dietary Supplement: Coromega Omega-3 Squeeze

• Registration Number: NCT01488747
• Lead Sponsor: USDA Grand Forks Human Nutrition Research Center

Brief Summary

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools.

The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11
• Study First Submitted: 2011-12-06
• Study First Submitted QC: 2011-12-07
• Study First Posted: 2011-12-08
• Primary Completion: 2012-10
• Study Completion: 2016-04
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-01
• Last Update Posted: 2018-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Healthy adults ages 18 to 60.
2. Body mass index between 22 and 32 kg/m2.
3. Medical history (interview) demonstrating good health.
4. Nonsmoker.
5. Consumption of a typical American diet with no unusual dietary habits.
6. Willingness to comply with the study protocol.
7. Low reported n-3 intake (<100 mg/d) on the Omega-3 Checklist

Exclusion Criteria

1. Any active, uncontrolled medical problem.
2. Consumption of essential fatty acid supplements within the past 6 months.
3. Use of lipid lowering drugs.
4. Fish consumption greater than 1 fish meal per week

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Coromega Nectar	Coromega Nectar	12.22 g
Barleans Swirl	Barleans Swirl	17.45 g
Nordic Omega-3 Softgel	Nordic Omega-3 Softgel	4 softgels
Coromega Omega-3 Squeeze	Coromega Omega-3 Squeeze	5.03 g

Primary Outcome Measures

Name	Time	Method
Area under the curve for phospholipid fatty acids	48 hours	Evaluation of the bioavailability of fatty acids from fish oil supplements

Secondary Outcome Measures

Name	Time	Method
Area under the curve for chylomicron fatty acids	48 hours	Evaluation of the bioavailability of fatty acids from fish oil supplements

Trial Locations

Locations (1)

USDA Grand Forks Human Nutrition Research Center; 🇺🇸 Grand Forks, North Dakota, United States